“Global KRAS Inhibitors Market & Clinical Trials Forecast 2028” Report Highlights:
- Global KRAS Inhibitors Market Opportunity: > USD 4 Billion by 2028
- Initially US To Dominate KRAS Inhibitors Market: >70% Market Share
- Number of KRAS Inhibitors In Trials: > 45 Drugs
- Number of Approved Drugs: 1 (Lumakras)
- Lumakras Dosage, Sales, Patent & Price Insight
- Solid Tumors Targeted Drugs Dominating The Clinical Trials
- Global KRAS Inhibitors Market Trends & Dynamics
- Global KRAS Inhibitors Market Future Opportunity Outlook
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) has emerged out to be potential target in the management of several cancers. Lumakras (sotorasib) developed by Amgen is potential first in class KRASG12C inhibitor used for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non- small cell lung cancer (NSCLC), following at least one prior systemic therapy. The drug entered the US market in 2021 and is thought to revolutionize the paradigm treatment of KRAS mutated non-small cell lung cancer. In short span of time, the sales of the drug has crossed US$ 90 Million which is suggesting promising future growth rates of these drugs in cancer therapeutics market. The encouraging response of Lumakras in the global market has propelled further research and development activities in KRAS inhibitor market.
Adagrasib developed by Mirati Therapeutics is another leading KRAS inhibitor which is expected to gain entry into the market in 2022. In recent clinical trial, Adagrasib monotherapy demonstrated promising results in patients with previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC) by significantly enhancing the objective response and disease control rates (DCR), as well as overall survival (OS). Based on these encouraging results, company has submitted new drug application in US as well as in Europe. The prescription drug free user act (PDUFA) date is December 14, 2022. Another, JAB-21822 developed by Jacobio has shown superior pharmacokinetic profile and favorable tolerability as well as potential for superior dosing profile in comparison with its competitors. The prom8ising clinical data suggest future launch of these drugs in the market.
To further target the multifactorial and complex nature of cancer, researchers are evaluating KRAS inhibitor in combination therapy with other cancer targeting regimens. Recently in 2022, Erasca has announced an clinical trial to evaluate the ERK1/2 inhibitor ERAS-007 in combination with a KRAS G12C inhibitor in KRAS G12C-driven non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Additional preclinical and clinical research trials will be conducted to further understand the activity and safety of this combination in these patient populations.
The global KRAS inhibitor market is higly competitive with several key players including Amgen, Mirati Therapeutics, Novartis, Merck, Revolution Medicines, Merck, Johnson & Johnson, Gilead Sciences, Eli Lilly, and others. New product launch, development, and commercialization, and mergers and acquisitions are key strategies used by market players to maintain their position in market. Agenus and Targovax have also entered into clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccine with Agenus’s clinically validated and FDA approved QS-21 Stimulon adjuvant. Under the collaboration with Tagrovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.
As per our report findings, the global KRAS inhibitor market is expected to surpass US$ 4 Billion by 2028. The huge growth rates of the market is mainly due to huge adoption rate of Lumakras as well as promising drug pipeline which is expected to gain approval in coming years. To date, a cocktail of KRAS inhibitors are currently present in clinical trials which are expected to enter the market during forecast period. The pipeline of KRAS inhibitors is highly crowded and consists of several candidates including Adagrasib, RMC-6291, JDQ443, JAB-21822, GDC-6036, amongst others. Other factors including rising geriatric population with increased risk of developing cancer, increasing emphasis on research and development, and favorable government policies for life science companies and government funding are also expected to boost the KRAS inhibitors demand in near future. Further launch of biomarker tests such as the therascreen KRAS RCQ PCR kit (therascreen KRAS Kit) will also drive the growth in near future.